Home Healthcare Pharmaceuticals Anti-HIV Drugs Market

Anti-HIV Drugs Market Size, Share & Trends Analysis Report By Medication Class (Multi-class combination drugs, Nucleoside reverse transcriptase inhibitors (NRTIs), Non-nucleoside reverse transcriptase inhibitors (NNRTIs), HIV integrase strand transfer inhibitors), By Distribution Channel (Hospital pharmacies, Retail pharmacies, E-commerce) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: August 03, 2026 | Author: Debashree B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Anti-HIV Drugs Market, By Medication Class 2022-2034 (USD MILLION/ Units)
    1. Multi-class combination drugs
    2. Nucleoside reverse transcriptase inhibitors (NRTIs)
    3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
    4. HIV integrase strand transfer inhibitors
  2. Anti-HIV Drugs Market, By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital pharmacies
    2. Retail pharmacies
    3. E-commerce
  3. Regional Anti-HIV Drugs Market
    1. North America
      1. North America Anti-HIV Drugs Market By Medication Class 2022-2034 (USD MILLION/ Units)
        1. Multi-class combination drugs
        2. Nucleoside reverse transcriptase inhibitors (NRTIs)
        3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
        4. HIV integrase strand transfer inhibitors
      2. North America Anti-HIV Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital pharmacies
        2. Retail pharmacies
        3. E-commerce
      3. U.S.
        1. Multi-class combination drugs
        2. Nucleoside reverse transcriptase inhibitors (NRTIs)
        3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
        4. HIV integrase strand transfer inhibitors
        5. Hospital pharmacies
        6. Retail pharmacies
        7. E-commerce
      4. Canada
        1. Multi-class combination drugs
        2. Nucleoside reverse transcriptase inhibitors (NRTIs)
        3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
        4. HIV integrase strand transfer inhibitors
        5. Hospital pharmacies
        6. Retail pharmacies
        7. E-commerce
    2. Europe
      1. Europe Anti-HIV Drugs Market By Medication Class 2022-2034 (USD MILLION/ Units)
        1. Multi-class combination drugs
        2. Nucleoside reverse transcriptase inhibitors (NRTIs)
        3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
        4. HIV integrase strand transfer inhibitors
      2. Europe Anti-HIV Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital pharmacies
        2. Retail pharmacies
        3. E-commerce
      3. U.K.
        1. Multi-class combination drugs
        2. Nucleoside reverse transcriptase inhibitors (NRTIs)
        3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
        4. HIV integrase strand transfer inhibitors
        5. Hospital pharmacies
        6. Retail pharmacies
        7. E-commerce
      4. Germany
        1. Multi-class combination drugs
        2. Nucleoside reverse transcriptase inhibitors (NRTIs)
        3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
        4. HIV integrase strand transfer inhibitors
        5. Hospital pharmacies
        6. Retail pharmacies
        7. E-commerce
      5. France
        1. Multi-class combination drugs
        2. Nucleoside reverse transcriptase inhibitors (NRTIs)
        3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
        4. HIV integrase strand transfer inhibitors
        5. Hospital pharmacies
        6. Retail pharmacies
        7. E-commerce
      6. Spain
        1. Multi-class combination drugs
        2. Nucleoside reverse transcriptase inhibitors (NRTIs)
        3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
        4. HIV integrase strand transfer inhibitors
        5. Hospital pharmacies
        6. Retail pharmacies
        7. E-commerce
      7. Italy
        1. Multi-class combination drugs
        2. Nucleoside reverse transcriptase inhibitors (NRTIs)
        3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
        4. HIV integrase strand transfer inhibitors
        5. Hospital pharmacies
        6. Retail pharmacies
        7. E-commerce
      8. Russia
        1. Multi-class combination drugs
        2. Nucleoside reverse transcriptase inhibitors (NRTIs)
        3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
        4. HIV integrase strand transfer inhibitors
        5. Hospital pharmacies
        6. Retail pharmacies
        7. E-commerce
      9. Nordic
        1. Multi-class combination drugs
        2. Nucleoside reverse transcriptase inhibitors (NRTIs)
        3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
        4. HIV integrase strand transfer inhibitors
        5. Hospital pharmacies
        6. Retail pharmacies
        7. E-commerce
      10. Benelux
        1. Multi-class combination drugs
        2. Nucleoside reverse transcriptase inhibitors (NRTIs)
        3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
        4. HIV integrase strand transfer inhibitors
        5. Hospital pharmacies
        6. Retail pharmacies
        7. E-commerce
      11. Rest of Europe
        1. Multi-class combination drugs
        2. Nucleoside reverse transcriptase inhibitors (NRTIs)
        3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
        4. HIV integrase strand transfer inhibitors
        5. Hospital pharmacies
        6. Retail pharmacies
        7. E-commerce
    3. APAC
      1. APAC Anti-HIV Drugs Market By Medication Class 2022-2034 (USD MILLION/ Units)
        1. Multi-class combination drugs
        2. Nucleoside reverse transcriptase inhibitors (NRTIs)
        3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
        4. HIV integrase strand transfer inhibitors
      2. APAC Anti-HIV Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital pharmacies
        2. Retail pharmacies
        3. E-commerce
      3. China
        1. Multi-class combination drugs
        2. Nucleoside reverse transcriptase inhibitors (NRTIs)
        3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
        4. HIV integrase strand transfer inhibitors
        5. Hospital pharmacies
        6. Retail pharmacies
        7. E-commerce
      4. Korea
        1. Multi-class combination drugs
        2. Nucleoside reverse transcriptase inhibitors (NRTIs)
        3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
        4. HIV integrase strand transfer inhibitors
        5. Hospital pharmacies
        6. Retail pharmacies
        7. E-commerce
      5. Japan
        1. Multi-class combination drugs
        2. Nucleoside reverse transcriptase inhibitors (NRTIs)
        3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
        4. HIV integrase strand transfer inhibitors
        5. Hospital pharmacies
        6. Retail pharmacies
        7. E-commerce
      6. India
        1. Multi-class combination drugs
        2. Nucleoside reverse transcriptase inhibitors (NRTIs)
        3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
        4. HIV integrase strand transfer inhibitors
        5. Hospital pharmacies
        6. Retail pharmacies
        7. E-commerce
      7. Australia
        1. Multi-class combination drugs
        2. Nucleoside reverse transcriptase inhibitors (NRTIs)
        3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
        4. HIV integrase strand transfer inhibitors
        5. Hospital pharmacies
        6. Retail pharmacies
        7. E-commerce
      8. Taiwan
        1. Multi-class combination drugs
        2. Nucleoside reverse transcriptase inhibitors (NRTIs)
        3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
        4. HIV integrase strand transfer inhibitors
        5. Hospital pharmacies
        6. Retail pharmacies
        7. E-commerce
      9. South East Asia
        1. Multi-class combination drugs
        2. Nucleoside reverse transcriptase inhibitors (NRTIs)
        3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
        4. HIV integrase strand transfer inhibitors
        5. Hospital pharmacies
        6. Retail pharmacies
        7. E-commerce
      10. Rest of Asia-Pacific
        1. Multi-class combination drugs
        2. Nucleoside reverse transcriptase inhibitors (NRTIs)
        3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
        4. HIV integrase strand transfer inhibitors
        5. Hospital pharmacies
        6. Retail pharmacies
        7. E-commerce
    4. Middle East and Africa
      1. Middle East and Africa Anti-HIV Drugs Market By Medication Class 2022-2034 (USD MILLION/ Units)
        1. Multi-class combination drugs
        2. Nucleoside reverse transcriptase inhibitors (NRTIs)
        3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
        4. HIV integrase strand transfer inhibitors
      2. Middle East and Africa Anti-HIV Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital pharmacies
        2. Retail pharmacies
        3. E-commerce
      3. UAE
        1. Multi-class combination drugs
        2. Nucleoside reverse transcriptase inhibitors (NRTIs)
        3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
        4. HIV integrase strand transfer inhibitors
        5. Hospital pharmacies
        6. Retail pharmacies
        7. E-commerce
      4. Turkey
        1. Multi-class combination drugs
        2. Nucleoside reverse transcriptase inhibitors (NRTIs)
        3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
        4. HIV integrase strand transfer inhibitors
        5. Hospital pharmacies
        6. Retail pharmacies
        7. E-commerce
      5. Saudi Arabia
        1. Multi-class combination drugs
        2. Nucleoside reverse transcriptase inhibitors (NRTIs)
        3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
        4. HIV integrase strand transfer inhibitors
        5. Hospital pharmacies
        6. Retail pharmacies
        7. E-commerce
      6. South Africa
        1. Multi-class combination drugs
        2. Nucleoside reverse transcriptase inhibitors (NRTIs)
        3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
        4. HIV integrase strand transfer inhibitors
        5. Hospital pharmacies
        6. Retail pharmacies
        7. E-commerce
      7. Egypt
        1. Multi-class combination drugs
        2. Nucleoside reverse transcriptase inhibitors (NRTIs)
        3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
        4. HIV integrase strand transfer inhibitors
        5. Hospital pharmacies
        6. Retail pharmacies
        7. E-commerce
      8. Nigeria
        1. Multi-class combination drugs
        2. Nucleoside reverse transcriptase inhibitors (NRTIs)
        3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
        4. HIV integrase strand transfer inhibitors
        5. Hospital pharmacies
        6. Retail pharmacies
        7. E-commerce
      9. Rest of MEA
        1. Multi-class combination drugs
        2. Nucleoside reverse transcriptase inhibitors (NRTIs)
        3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
        4. HIV integrase strand transfer inhibitors
        5. Hospital pharmacies
        6. Retail pharmacies
        7. E-commerce
    5. LATAM
      1. LATAM Anti-HIV Drugs Market By Medication Class 2022-2034 (USD MILLION/ Units)
        1. Multi-class combination drugs
        2. Nucleoside reverse transcriptase inhibitors (NRTIs)
        3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
        4. HIV integrase strand transfer inhibitors
      2. LATAM Anti-HIV Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital pharmacies
        2. Retail pharmacies
        3. E-commerce
      3. Brazil
        1. Multi-class combination drugs
        2. Nucleoside reverse transcriptase inhibitors (NRTIs)
        3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
        4. HIV integrase strand transfer inhibitors
        5. Hospital pharmacies
        6. Retail pharmacies
        7. E-commerce
      4. Mexico
        1. Multi-class combination drugs
        2. Nucleoside reverse transcriptase inhibitors (NRTIs)
        3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
        4. HIV integrase strand transfer inhibitors
        5. Hospital pharmacies
        6. Retail pharmacies
        7. E-commerce
      5. Argentina
        1. Multi-class combination drugs
        2. Nucleoside reverse transcriptase inhibitors (NRTIs)
        3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
        4. HIV integrase strand transfer inhibitors
        5. Hospital pharmacies
        6. Retail pharmacies
        7. E-commerce
      6. Chile
        1. Multi-class combination drugs
        2. Nucleoside reverse transcriptase inhibitors (NRTIs)
        3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
        4. HIV integrase strand transfer inhibitors
        5. Hospital pharmacies
        6. Retail pharmacies
        7. E-commerce
      7. Colombia
        1. Multi-class combination drugs
        2. Nucleoside reverse transcriptase inhibitors (NRTIs)
        3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
        4. HIV integrase strand transfer inhibitors
        5. Hospital pharmacies
        6. Retail pharmacies
        7. E-commerce
      8. Rest of LATAM
        1. Multi-class combination drugs
        2. Nucleoside reverse transcriptase inhibitors (NRTIs)
        3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
        4. HIV integrase strand transfer inhibitors
        5. Hospital pharmacies
        6. Retail pharmacies
        7. E-commerce
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.